International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?

Giacomelli, Roberto; Afeltra, Antonella; Alunno, Alessia; Baldini, Chiara; Bartoloni, Elena; Berardicurti, Onorina; Carubbi, Francesco; Cauli, Alberto; Cervera, Ricard; Ciccia, Francesco; Cipriani, Paola; Conti, Fabrizio; Vita, Salvatore De; Benedetto, Paola Di; Doria, Andrea; Drosos, Alexandros A.; Favalli, Ennio Giulio; Gandolfo, Saviana; Gatto, Mariele; Grembiale, Rosa Daniela; Liakouli, Vasiliki; Lories, Rik; Lubrano, Ennio; Lunardi, Claudio; Margiotta, Domenico Paolo Emanuele; Massaro, Laura; Meroni, Pier Luigi; Minniti, Antonina; Navarini, Luca; Pendolino, Monica; Perosa, Federico; Pers, Jacques Olivier; Prete, Marcella; Priori, Roberta; Puppo, Francesco; Quartuccio, Luca; Ruffatti, Amelia; Ruscitti, Piero; Russo, Barbara; Sarzi-Puttini, Piercarlo; Shoenfeld, Yehuda; Somarakis, George; Spinelli, Francesca Romana; Tinazzi, Elisa; Triolo, Giovanni; Ursini, Francesco; Valentini, Gabriele; Valesini, Guido; Vettori, Serena; Vitali, Claudio; Tzioufas, Athanasios G.

doi:10.1016/j.autrev.2017.07.012

Cited by 115 publications

(79 citation statements)

References 180 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There was no high rate of comorbidities, being thyroid disease and SLE the most prevalent. Certainly, in patients carrying aPL it is possible to stay in a grey zone with other autoimmune diseases [26]. Thus, a genetic predisposition [27] and a trigger that may damage endothelial surface [28] with aPL generation could explain its heterogeneous presentation.…”

Section: Discussionmentioning

confidence: 99%

The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases

Alijotas‐Reig¹,

Esteve-Valverde

Ferrer‐Oliveras³

et al. 2019

Autoimmunity Reviews

Self Cite

125

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases

Alijotas‐Reig¹,

Esteve-Valverde

Ferrer‐Oliveras³

et al. 2019

Autoimmunity Reviews

Self Cite

125

View full text Add to dashboard Cite

show abstract

“…This is a member of the TIM gene family and is expressed by T helper type 2 (Th2) cells and macrophages in the context of the proinflammatory milieu [32,33]. The binding H-ferritin/TIM-2 may activate these immune cells, leading to subsequent pathogenic proinflammatory process [12,[18][19][20][21]. Taking together all these mechanisms, it is possible to speculate that the enhanced tissue expression of H-ferritin, via a vicious loop, may perpetuate the production of proinflammatory cytokines, possible therapeutic targets in MAS [16,17,22,23,27,28].…”

Section: Discussionmentioning

confidence: 99%

H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome

Ruscitti

Cipriani

Benedetto

et al. 2017

Clinical and Experimental Immunology

View full text Add to dashboard Cite

Macrophage activation syndrome (MAS) is hyperinflammatory life-threatening syndrome, associated typically with high levels of serum ferritin. This is an iron storage protein including heavy (H) and light (L) subunits, categorized on their molecular weight. The H-/L subunits ratio may be different in tissues, depending on the specific tissue and pathophysiological status. In this study, we analysed the bone marrow (BM) biopsies of adult MAS patients to assess the presence of: (i) H-ferritin and L-ferritin; (ii) CD68 /H-ferritin and CD68 /L-ferritin ; and (iii) interleukin (IL)-1β, tumour necrosis factor (TNF) and interferon (IFN)-γ. We also explored possible correlations of these results with clinical data. H-ferritin, IL-1β, TNF and IFN-γ were increased significantly in MAS. Furthermore, an increased number of CD68 /H-ferritin cells and an infiltrate of cells co-expressing H-ferritin and IL-12, suggesting an infiltrate of M1 macrophages, were observed. H-ferritin levels and CD68 /H-ferritin cells were correlated with haematological involvement of the disease, serum ferritin and C-reactive protein. L-ferritin and CD68 /L-ferritin cells did not correlate with these parameters. In conclusion, during MAS, H-ferritin, CD68 /H-ferritin cells and proinflammatory cytokines were increased significantly in the BM inflammatory infiltrate, pointing out a possible vicious pathogenic loop. To date, H-ferritin and CD68 /H-ferritin were associated significantly with haematological involvement of the disease, suggesting biomarkers assessing severity of clinical picture.

show abstract

“…The overarching aim of this workshop is to clarify the meaning of specific biomarkers during autoimmune diseases; their possible role in confirming diagnosis, predicting outcome and suggesting specific treatments. The general methodology based on a Delphi Technique-based aimed at producing, starting from the results of a systematic review of available literature, a set of statements summarising the consensus among the Experts, as previously reported [12]. This systematic review has been designed to be included in an International project named "Clinical and as final statements, while the others were rejected outright.…”

Section: Aims Of the Projectmentioning

confidence: 99%

Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis

Giacomelli

Afeltra

Alunno

et al. 2019

Autoimmunity Reviews

Self Cite

101

View full text Add to dashboard Cite

Autoimmune rheumatic diseases are characterised by an abnormal immune system response, complement activation, cytokines dysregulation and inflammation. In last years, despite many progresses in managing these patients, it has been shown that clinical remission is reached in less than 50% of patients and a personalised and tailored therapeutic approach is still lacking resulting in a significant gap between guidelines and real-world practice. In this context, the need for biomarkers facilitating early diagnosis and profiling those individuals at the highest risk for a poor outcome has become of crucial interest. A biomarker generally refers to a measured characteristic which may be used as an indicator of some biological state or condition. Three different types of medical biomarkers has been suggested: i. mechanistic markers; ii. clinical disease markers; iii. therapeutic markers. A combination of biomarkers from these different groups could be used for an ideal more accurate diagnosis and treatment. However, although a growing body of evidence is focused on improving biomarkers, a significant amount of this information is not integrated on standard clinical care. The overarching aim of this work was to clarify the meaning of specific biomarkers during autoimmune diseases; their possible role in confirming diagnosis, predicting outcome and suggesting specific treatments.

show abstract

International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?

Cited by 115 publications

References 180 publications

The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases

The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases

H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome

Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis

Contact Info

Product

Resources

About